Ocuphire Pharma Results
Baseline Characteristics for ZETA-1 Trial (Continued)
Key Visual Metrics in Diabetic Study Population
Ocuphire
PHARMA
Study Eye Screening CST (um):
Parameter
Fellow Eye Screening CST (um)*:
Study Eye BCVA:
Fellow Eye BCVA:
IOP Study Eye and Fellow Eye (mmHg):
Diabetic Status (Years):
Study Eye with anti-VEGF injections
within 6 months prior to Screening
Fellow Eye with anti-VEGF injections
within 6 months prior to Screening
Source: ZETA-1 Demographics and Baseline Characteristics
* N=102 due to a fellow eye not being graded.
mean
(range)
mean
(range)
mean
(range)
mean
(range)
mean
(range)
mean
(range)
270
(203-319)
289
(211-491)
Letters Read:
80
(60-93)
Letters Read:
77
(0-91)
15
(8-22)
16
(0-58)
None
15
Total N = 103
Snellen Equivalent:
20/25
(20/63-20/15)
Snellen Equivalent:
20/32
(20/1000-20/15)
47View entire presentation